Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | PLD2 | O14939 | 1/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941636 | 0.94 | NPC1 (0.49) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941469 | 0.91 | NPC1 (0.55) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941706 | 0.89 | MAOA (0.54) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941711 | 0.87 | EGFR (0.50) | NPC1RAB9APLD2PLD1EGFR | |
| SCHEMBL13941634 | 0.87 | EGFR (0.56) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941709 | 0.86 | EGFR (0.49) | NPC1RAB9APLD2PLD1EGFR | |
| SCHEMBL13941579 | 0.85 | EGFR (0.47) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941473 | 0.84 | NPC1 (0.49) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941702 | 0.84 | EGFR (0.48) | NPC1RAB9AMAPTPLD2PLD1 | |
| SCHEMBL13941721 | 0.84 | PLD2 (0.43) | NPC1RAB9AMAPTPLD2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | NPC1 3750/4885RAB9A 2366/4885MAPT 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.